1. Soykan I, Sivri B, Sarosiek I, Kiernan B, McCallum RW. Demography, clinical characteristics, psychological and abuse profiles, treatment, and long-term follow-up of patients with gastroparesis. Dig Dis Sci. 1998;43:2398–2404. [PubMed] [Google Scholar]
2. Park MI, Camilleri M. Gastroparesis: clinical update. Am J Gastroenterol. 2006;101:1129–1139. [PubMed] [Google Scholar]
3. Huizinga JD. Neural injury, repair, and adaptation in the GI tract. IV. Pathophysiology of GI motility related to interstitial cells of Cajal. Am J Physiol. 1998;275:G381–G386. [PubMed] [Google Scholar]
4. Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care. 2003;26:1553–1579. [PubMed] [Google Scholar]
5. Ziegler D, Schadewaldt P, Pour Mirza A, Piolot R, Schommartz B, Reinhardt M, Vosberg H, Brosicke H, Gries FA. [13C]octanoic acid breath test for non-invasive assessment of gastric emptying in diabetic patients: validation and relationship to gastric symptoms and cardiovascular autonomic function. Diabetologia. 1996;39:823–830. [PubMed] [Google Scholar]
6. Ordog T, Takayama I, Cheung WK, Ward SM, Sanders KM. Remodeling of networks of interstitial cells of Cajal in a murine model of diabetic gastroparesis. Diabetes. 2000;49:1731–1739. [PubMed] [Google Scholar]
7. Ali T, Hasan M, Hamadani M, Harty RF. Gastroparesis. South Med J. 2007;100:281–286. [PubMed] [Google Scholar]
8. Peeters TL. New motilin agonists: a long and winding road. Neurogastroenterol Motil. 2006;18:1–5. [PubMed] [Google Scholar]
9. Murray CD, Martin NM, Patterson M, Taylor SA, Ghatei MA, Kamm MA, Johnston C, Bloom SR, Emmanuel AV. Ghrelin enhances gastric emptying in diabetic gastroparesis: a double blind, placebo controlled, crossover study. Gut. 2005;54:1693–1698. [PMC free article] [PubMed] [Google Scholar]
10. Parkman HP, Hasler WL, Fisher RS. American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology. 2004;127:1592–1622. [PubMed] [Google Scholar]
11. Parkman HP, Schwartz SS. Esophagitis and gastroduodenal disorders associated with diabetic gastroparesis. Arch Intern Med. 1987;147:1477–1480. [PubMed] [Google Scholar]
12. Abell TL, Bernstein RK, Cutts T, Farrugia G, Forster J, Hasler WL, McCallum RW, Olden KW, Parkman HP, Parrish CR, et al. Treatment of gastroparesis: a multidisciplinary clinical review. Neurogastroenterol Motil. 2006;18:263–283. [PubMed] [Google Scholar]
13. Revicki DA, Rentz AM, Dubois D, Kahrilas P, Stanghellini V, Talley NJ, Tack J. Gastroparesis Cardinal Symptom Index (GCSI): development and validation of a patient reported assessment of severity of gastroparesis symptoms. Qual Life Res. 2004;13:833–844. [PubMed] [Google Scholar]
14. Hoogerwerf WA, Pasricha PJ, Kalloo AN, Schuster MM. Pain: the overlooked symptom in gastroparesis. Am J Gastroenterol. 1999;94:1029–1033. [PubMed] [Google Scholar]
15. Boccia G, Buonavolonta R, Coccorullo P, Manguso F, Fuiano L, Staiano A. Dyspeptic symptoms in children: the result of a constipation-induced cologastric brake? Clin Gastroenterol Hepatol. 2008;6:556–560. [PubMed] [Google Scholar]
16. Parkman HP, Schwartz SS. Esophagitis and gastroduodenal disorders associated with diabetic gastroparesis. Arch Intern Med. 1987;147:1477–1480. [PubMed] [Google Scholar]
17. Blam ME, Lichtenstein GR. A new endoscopic technique for the removal of gastric phytobezoars. Gastrointest Endosc. 2000;52:404–408. [PubMed] [Google Scholar]
18. Abell TL, Camilleri M, Donohoe K, Hasler WL, Lin HC, Maurer AH, McCallum RW, Nowak T, Nusynowitz ML, Parkman HP, et al. Consensus recommendations for gastric emptying scintigraphy: a joint report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. Am J Gastroenterol. 2008;103:753–763. [PubMed] [Google Scholar]
19. Camilleri M, Zinsmeister AR, Greydanus MP, Brown ML, Proano M. Towards a less costly but accurate test of gastric emptying and small bowel transit. Dig Dis Sci. 1991;36:609–615. [PubMed] [Google Scholar]
20. Feldman M, Smith HJ, Simon TR. Gastric emptying of solid radiopaque markers: studies in healthy subjects and diabetic patients. Gastroenterology. 1984;87:895–902. [PubMed] [Google Scholar]
21. Bateman DN, Whittingham TA. Measurement of gastric emptying by real-time ultrasound. Gut. 1982;23:524–527. [PMC free article] [PubMed] [Google Scholar]
22. Bolondi L, Bortolotti M, Santi V, Calletti T, Gaiani S, Labo G. Measurement of gastric emptying time by real-time ultrasonography. Gastroenterology. 1985;89:752–759. [PubMed] [Google Scholar]
23. Holt S, Cervantes J, Wilkinson AA, Wallace JH. Measurement of gastric emptying rate in humans by real-time ultrasound. Gastroenterology. 1986;90:918–923. [PubMed] [Google Scholar]
24. Gentilcore D, Hausken T, Horowitz M, Jones KL. Measurements of gastric emptying of low- and high-nutrient liquids using 3D ultrasonography and scintigraphy in healthy subjects. Neurogastroenterol Motil. 2006;18:1062–1068. [PubMed] [Google Scholar]
25. Gilja OH, Detmer PR, Jong JM, Leotta DF, Li XN, Beach KW, Martin R, Strandness DE Jr. Intragastric distribution and gastric emptying assessed by three-dimensional ultrasonography. Gastroenterology. 1997;113:38–49. [PubMed] [Google Scholar]
26. Gilja OH. Ultrasound of the stomach--the EUROSON lecture 2006. Ultraschall Med. 2007;28:32–39. [PubMed] [Google Scholar]
27. Kim DY, Myung SJ, Camilleri M. Novel testing of human gastric motor and sensory functions: rationale, methods, and potential applications in clinical practice. Am J Gastroenterol. 2000;95:3365–3373. [PubMed] [Google Scholar]
28. Ajaj W, Goehde SC, Papanikolaou N, Holtmann G, Ruehm SG, Debatin JF, Lauenstein TC. Real time high resolution magnetic resonance imaging for the assessment of gastric motility disorders. Gut. 2004;53:1256–1261. [PMC free article] [PubMed] [Google Scholar]
29. Kunz P, Feinle C, Schwizer W, Fried M, Boesiger P. Assessment of gastric motor function during the emptying of solid and liquid meals in humans by MRI. J Magn Reson Imaging. 1999;9:75–80. [PubMed] [Google Scholar]
30. Feinle C, Kunz P, Boesiger P, Fried M, Schwizer W. Scintigraphic validation of a magnetic resonance imaging method to study gastric emptying of a solid meal in humans. Gut. 1999;44:106–111. [PMC free article] [PubMed] [Google Scholar]
31. Kuiken SD, Samsom M, Camilleri M, Mullan BP, Burton DD, Kost LJ, Hardyman TJ, Brinkmann BH, O'Connor MK. Development of a test to measure gastric accommodation in humans. Am J Physiol. 1999;277:G1217–G1221. [PubMed] [Google Scholar]
32. Viramontes BE, Kim DY, Camilleri M, Lee JS, Stephens D, Burton DD, Thomforde GM, Klein PD, Zinsmeister AR. Validation of a stable isotope gastric emptying test for normal, accelerated or delayed gastric emptying. Neurogastroenterol Motil. 2001;13:567–574. [PubMed] [Google Scholar]
33. Ghoos YF, Maes BD, Geypens BJ, Mys G, Hiele MI, Rutgeerts PJ, Vantrappen G. Measurement of gastric emptying rate of solids by means of a carbon-labeled octanoic acid breath test. Gastroenterology. 1993;104:1640–1647. [PubMed] [Google Scholar]
34. Braden B, Adams S, Duan LP, Orth KH, Maul FD, Lembcke B, Hor G, Caspary WF. The [13C]acetate breath test accurately reflects gastric emptying of liquids in both liquid and semisolid test meals. Gastroenterology. 1995;108:1048–1055. [PubMed] [Google Scholar]
35. Kuo B, McCallum RW, Koch KL, Sitrin MD, Wo JM, Chey WD, Hasler WL, Lackner JM, Katz LA, Semler JR, et al. Comparison of gastric emptying of a nondigestible capsule to a radio-labelled meal in healthy and gastroparetic subjects. Aliment Pharmacol Ther. 2008;27:186–196. [PubMed] [Google Scholar]
36. Mearin F, Camilleri M, Malagelada JR. Pyloric dysfunction in diabetics with recurrent nausea and vomiting. Gastroenterology. 1986;90:1919–1925. [PubMed] [Google Scholar]
37. Camilleri M, Malagelada JR. Abnormal intestinal motility in diabetics with the gastroparesis syndrome. Eur J Clin Invest. 1984;14:420–427. [PubMed] [Google Scholar]
38. Soffer E, Thongsawat S. Clinical value of duodenojejunal manometry. Its usefulness in diagnosis and management of patients with gastrointestinal symptoms. Dig Dis Sci. 1996;41:859–863. [PubMed] [Google Scholar]
39. Camilleri M, Hasler WL, Parkman HP, Quigley EM, Soffer E. Measurement of gastrointestinal motility in the GI laboratory. Gastroenterology. 1998;115:747–762. [PubMed] [Google Scholar]
40. Parkman HP, Hasler WL, Barnett JL, Eaker EY. Electrogastrography: a document prepared by the gastric section of the American Motility Society Clinical GI Motility Testing Task Force. Neurogastroenterol Motil. 2003;15:89–102. [PubMed] [Google Scholar]
41. Azpiroz F, Malagelada JR. Gastric tone measured by an electronic barostat in health and postsurgical gastroparesis. Gastroenterology. 1987;92:934–943. [PubMed] [Google Scholar]
42. Quigley EM, Hasler WL, Parkman HP. AGA technical review on nausea and vomiting. Gastroenterology. 2001;120:263–286. [PubMed] [Google Scholar]
43. Patrick A, Epstein O. Review article: gastroparesis. Aliment Pharmacol Ther. 2008;27:724–740. [PubMed] [Google Scholar]
44. Petrakis IE, Vrachassotakis N, Sciacca V, Vassilakis SI, Chalkiadakis G. Hyperglycaemia attenuates erythromycin-induced acceleration of solid-phase gastric emptying in idiopathic and diabetic gastroparesis. Scand J Gastroenterol. 1999;34:396–403. [PubMed] [Google Scholar]
45. Gentilcore D, O'Donovan D, Jones KL, Horowitz M. Nutrition therapy for diabetic gastroparesis. Curr Diab Rep. 2003;3:418–426. [PubMed] [Google Scholar]
46. Talley NJ. Diabetic gastropathy and prokinetics. Am J Gastroenterol. 2003;98:264–271. [PubMed] [Google Scholar]
47. Sturm A, Holtmann G, Goebell H, Gerken G. Prokinetics in patients with gastroparesis: a systematic analysis. Digestion. 1999;60:422–427. [PubMed] [Google Scholar]
48. Farrugia G, Macielag MJ, Peeters TL, Sarr MG, Galdes A, Szurszewski JH. Motilin and OHM-11526 activate a calcium current in human and canine jejunal circular smooth muscle. Am J Physiol. 1997;273:G404–G412. [PubMed] [Google Scholar]
49. DiBaise JK, Quigley EM. Efficacy of prolonged administration of intravenous erythromycin in an ambulatory setting as treatment of severe gastroparesis: one center's experience. J Clin Gastroenterol. 1999;28:131–134. [PubMed] [Google Scholar]
50. Kendall BJ, Chakravarti A, Kendall E, Soykan I, McCallum RW. The effect of intravenous erythromycin on solid meal gastric emptying in patients with chronic symptomatic post-vagotomy-antrectomy gastroparesis. Aliment Pharmacol Ther. 1997;11:381–385. [PubMed] [Google Scholar]
51. Peeters TL. Agonist effect of erythromycin and its analogues on motilin receptors. A new family of prokinetics? Clinical interest. Acta Gastroenterol Belg. 1993;56:257–260. [PubMed] [Google Scholar]
52. Parkman HP, Pagano AP, Vozzelli MA, Ryan JP. Gastrokinetic effects of erythromycin: myogenic and neurogenic mechanisms of action in rabbit stomach. Am J Physiol. 1995;269:G418–G426. [PubMed] [Google Scholar]
53. Richards RD, Davenport K, McCallum RW. The treatment of idiopathic and diabetic gastroparesis with acute intravenous and chronic oral erythromycin. Am J Gastroenterol. 1993;88:203–207. [PubMed] [Google Scholar]
54. Ramirez B, Eaker EY, Drane WE, Hocking MP, Sninsky CA. Erythromycin enhances gastric emptying in patients with gastroparesis after vagotomy and antrectomy. Dig Dis Sci. 1994;39:2295–2300. [PubMed] [Google Scholar]
55. Ehrenpreis ED, Zaitman D, Nellans H. Which form of erythromycin should be used to treat gastroparesis? A pharmaco*kinetic analysis. Aliment Pharmacol Ther. 1998;12:373–376. [PubMed] [Google Scholar]
56. Ray WA, Murray KT, Meredith S, Narasimhulu SS, Hall K, Stein CM. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med. 2004;351:1089–1096. [PubMed] [Google Scholar]
57. McCallum RW, Valenzuela G, Polepalle S, Spyker D. Subcutaneous metoclopramide in the treatment of symptomatic gastroparesis: clinical efficacy and pharmaco*kinetics. J Pharmacol Exp Ther. 1991;258:136–142. [PubMed] [Google Scholar]
58. Malagelada JR, Rees WD, Mazzotta LJ, Go VL. Gastric motor abnormalities in diabetic and postvagotomy gastroparesis: effect of metoclopramide and bethanechol. Gastroenterology. 1980;78:286–293. [PubMed] [Google Scholar]
59. Perkel MS, Moore C, Hersh T, Davidson ED. Metoclopramide therapy in patients with delayed gastric emptying: a randomized, double-blind study. Dig Dis Sci. 1979;24:662–666. [PubMed] [Google Scholar]
60. Snape WJ Jr, Battle WM, Schwartz SS, Braunstein SN, Goldstein HA, Alavi A. Metoclopramide to treat gastroparesis due to diabetes mellitus: a double-blind, controlled trial. Ann Intern Med. 1982;96:444–446. [PubMed] [Google Scholar]
61. Lata PF, Pigarelli DL. Chronic metoclopramide therapy for diabetic gastroparesis. Ann Pharmacother. 2003;37:122–126. [PubMed] [Google Scholar]
62. Ganzini L, Casey DE, Hoffman WF, McCall AL. The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders. Arch Intern Med. 1993;153:1469–1475. [PubMed] [Google Scholar]
63. Soykan I, Sarosiek I, McCallum RW. The effect of chronic oral domperidone therapy on gastrointestinal symptoms, gastric emptying, and quality of life in patients with gastroparesis. Am J Gastroenterol. 1997;92:976–980. [PubMed] [Google Scholar]
64. Horowitz M, Harding PE, Chatterton BE, Collins PJ, Shearman DJ. Acute and chronic effects of domperidone on gastric emptying in diabetic autonomic neuropathy. Dig Dis Sci. 1985;30:1–9. [PubMed] [Google Scholar]
65. Brogden RN, Carmine AA, Heel RC, Speight TM, Avery GS. Domperidone. A review of its pharmacological activity, pharmaco*kinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as an antiemetic. Drugs. 1982;24:360–400. [PubMed] [Google Scholar]
66. Bruera E, Villamayor R, Roca E, Barugel M, Tronge J, Chacon R. Q-T interval prolongation and ventricular fibrillation with i.v. domperidone. Cancer Treat Rep. 1986;70:545–546. [PubMed] [Google Scholar]
67. Degen L, Matzinger D, Merz M, Appel-Dingemanse S, Osborne S, Luchinger S, Bertold R, Maecke H, Beglinger C. Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment Pharmacol Ther. 2001;15:1745–1751. [PubMed] [Google Scholar]
68. Prather CM, Camilleri M, Zinsmeister AR, McKinzie S, Thomforde G. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology. 2000;118:463–468. [PubMed] [Google Scholar]
69. Griffin JP. Prepulsid withdrawn from UK & US markets. Adverse Drug React Toxicol Rev. 2000;19:177. [PubMed] [Google Scholar]
70. McCallum RW, Fink SM, Lerner E, Berkowitz DM. Effects of metoclopramide and bethanechol on delayed gastric emptying present in gastroesophageal reflux patients. Gastroenterology. 1983;84:1573–1577. [PubMed] [Google Scholar]
71. Moshiree B, Gupta V, Verne GN, Toskes PP. Azithromycin: a new therapy for gastroparesis. Gastroenterology. 2005;128:A547 (Abstract). [Google Scholar]
72. Huang BH, Wu CH, Hsia CP, Yin Chen C. Azithromycin-induced torsade de pointes. Pacing Clin Electrophysiol. 2007;30:1579–1582. [PubMed] [Google Scholar]
73. Kezerashvili A, Khattak H, Barsky A, Nazari R, Fisher JD. Azithromycin as a cause of QT-interval prolongation and torsade de pointes in the absence of other known precipitating factors. J Interv Card Electrophysiol. 2007;18:243–246. [PubMed] [Google Scholar]
74. Milberg P, Eckardt L, Bruns HJ, Biertz J, Ramtin S, Reinsch N, Fleischer D, Kirchhof P, Fabritz L, Breithardt G, et al. Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes. J Pharmacol Exp Ther. 2002;303:218–225. [PubMed] [Google Scholar]
75. McCallum RW, Cynshi O. Clinical trial: effect of mitemcinal (a motilin agonist) on gastric emptying in patients with gastroparesis - a randomized, multicentre, placebo-controlled study. Aliment Pharmacol Ther. 2007;26:1121–1130. [PubMed] [Google Scholar]
76. Park MI, Ferber I, Camilleri M, Allenby K, Trillo R, Burton D, Zinsmeister AR. Effect of atilmotin on gastrointestinal transit in healthy subjects: a randomized, placebo-controlled study. Neurogastroenterol Motil. 2006;18:28–36. [PubMed] [Google Scholar]
77. Murray CD, Martin NM, Patterson M, Taylor SA, Ghatei MA, Kamm MA, Johnston C, Bloom SR, Emmanuel AV. Ghrelin enhances gastric emptying in diabetic gastroparesis: a double blind, placebo controlled, crossover study. Gut. 2005;54:1693–1698. [PMC free article] [PubMed] [Google Scholar]
78. Tack J, Depoortere I, Bisschops R, Verbeke K, Janssens J, Peeters T. Influence of ghrelin on gastric emptying and meal-related symptoms in idiopathic gastroparesis. Aliment Pharmacol Ther. 2005;22:847–853. [PubMed] [Google Scholar]
79. Holtmann G, Talley NJ, Liebregts T, Adam B, Parow C. A placebo-controlled trial of itopride in functional dyspepsia. N Engl J Med. 2006;354:832–840. [PubMed] [Google Scholar]
80. Choung RS, Talley NJ, Peterson J, Camilleri M, Burton D, Harmsen WS, Zinsmeister AR. A double-blind, randomized, placebo-controlled trial of itopride (100 and 200 mg three times daily) on gastric motor and sensory function in healthy volunteers. Neurogastroenterol Motil. 2007;19:180–187. [PubMed] [Google Scholar]
81. Mansi C, Savarino V, Vigneri S, Sciaba L, Perilli D, Mele MR, Celle G. Effect of D2-dopamine receptor antagonist levosulpiride on diabetic cholecystoparesis: a double-blind crossover study. Aliment Pharmacol Ther. 1995;9:185–189. [PubMed] [Google Scholar]
82. Mansi C, Borro P, Giacomini M, Biagini R, Mele MR, Pandolfo N, Savarino V. Comparative effects of levosulpiride and cisapride on gastric emptying and symptoms in patients with functional dyspepsia and gastroparesis. Aliment Pharmacol Ther. 2000;14:561–569. [PubMed] [Google Scholar]
83. Mearin F, Rodrigo L, Perez-Mota A, Balboa A, Jimenez I, Sebastian JJ, Patan C. Levosulpiride and cisapride in the treatment of dysmotility-like functional dyspepsia: a randomized, double-masked trial. Clin Gastroenterol Hepatol. 2004;2:301–308. [PubMed] [Google Scholar]
84. Kanaizumi T, Nakano H, Matsui Y, Ishikawa H, Shimizu R, Park S, Kuriya N. Prokinetic effect of AS-4370 on gastric emptying in healthy adults. Eur J Clin Pharmacol. 1991;41:335–337. [PubMed] [Google Scholar]
85. Potet F, Bouyssou T, Escande D, Baro I. Gastrointestinal prokinetic drugs have different affinity for the human cardiac human ether-a-gogo K(+) channel. J Pharmacol Exp Ther. 2001;299:1007–1012. [PubMed] [Google Scholar]
86. Pasha SF, Lunsford TN, Lennon VA. Autoimmune gastrointestinal dysmotility treated successfully with pyridostigmine. Gastroenterology. 2006;131:1592–1596. [PubMed] [Google Scholar]
87. Ueki S, Seiki M, Yoneta T, Aita H, Chaki K, Hori Y, Morita H, Tagashira E, Itoh Z. Gastroprokinetic activity of nizatidine, a new H2-receptor antagonist, and its possible mechanism of action in dogs and rats. J Pharmacol Exp Ther. 1993;264:152–157. [PubMed] [Google Scholar]
88. Scarpignato C, Kisfalvi I, D'Amato M, Varga G. Effect of dexloxiglumide and spiroglumide, two new CCK-receptor antagonists, on gastric emptying and secretion in the rat: evaluation of their receptor selectivity in vivo. Aliment Pharmacol Ther. 1996;10:411–419. [PubMed] [Google Scholar]
89. Watkins CC, Sawa A, Jaffrey S, Blackshaw S, Barrow RK, Snyder SH, Ferris CD. Insulin restores neuronal nitric oxide synthase expression and function that is lost in diabetic gastropathy. J Clin Invest. 2000;106:373–384. [PMC free article] [PubMed] [Google Scholar]
90. Coleski R, Gonlachanvit S, Owyang C, Hasler WL. Selective reversal of hyperglycemia-evoked gastric myoelectric dysrhythmias by nitrergic stimulation in healthy humans. J Pharmacol Exp Ther. 2005;312:103–111. [PubMed] [Google Scholar]
91. Sarnelli G, Sifrim D, Janssens J, Tack J. Influence of sildenafil on gastric sensorimotor function in humans. Am J Physiol Gastrointest Liver Physiol. 2004;287:G988–G992. [PubMed] [Google Scholar]
92. Bortolotti M, Mari C, Lopilato C, La Rovere L, Miglioli M. Sildenafil inhibits gastroduodenal motility. Aliment Pharmacol Ther. 2001;15:157–161. [PubMed] [Google Scholar]
93. Netzer P, Gaia C, Lourens ST, Reber P, Wildi S, Noelpp U, Ritter EP, Ledermann H, Luscher D, Varga L, et al. Does intravenous ondansetron affect gastric emptying of a solid meal, gastric electrical activity or blood hormone levels in healthy volunteers? Aliment Pharmacol Ther. 2002;16:119–127. [PubMed] [Google Scholar]
94. Nielsen OH, Hvid-Jacobsen K, Lund P, Langoholz E. Gastric emptying and subjective symptoms of nausea: lack of effects of a 5-hydroxytryptamine-3 antagonist ondansetron on gastric emptying in patients with gastric stasis syndrome. Digestion. 1990;46:89–96. [PubMed] [Google Scholar]
95. Loldrup D, Langemark M, Hansen HJ, Olesen J, Bech P. Clomipramine and mianserin in chronic idiopathic pain syndrome. A placebo controlled study. Psychopharmacology (Berl) 1989;99:1–7. [PubMed] [Google Scholar]
96. Mertz H, Fass R, Kodner A, Yan-Go F, Fullerton S, Mayer EA. Effect of amitriptyline on symptoms, sleep, and visceral perception in patients with functional dyspepsia. Am J Gastroenterol. 1998;93:160–165. [PubMed] [Google Scholar]
97. Sawhney MS, Prakash C, Lustman PJ, Clouse RE. Tricyclic antidepressants for chronic vomiting in diabetic patients. Dig Dis Sci. 2007;52:418–424. [PubMed] [Google Scholar]
98. Dando TM, Perry CM. Aprepitant: a review of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs. 2004;64:777–794. [PubMed] [Google Scholar]
99. Diemunsch P, Schoeffler P, Bryssine B, Cheli-Muller LE, Lees J, McQuade BA, Spraggs CF. Antiemetic activity of the NK1 receptor antagonist GR205171 in the treatment of established postoperative nausea and vomiting after major gynaecological surgery. Br J Anaesth. 1999;82:274–276. [PubMed] [Google Scholar]
100. De Giorgio R, Barbara G, Stanghellini V, Cogliandro RF, Arrigoni A, Santini D, Ceccarelli C, Salvioli B, Rossini FP, Corinaldesi R. Idiopathic myenteric ganglionitis underlying intractable vomiting in a young adult. Eur J Gastroenterol Hepatol. 2000;12:613–616. [PubMed] [Google Scholar]
101. Gupta YK, Sharma M. Reversal of pyrogallol-induced delay in gastric emptying in rats by ginger (Zingiber officinale) Methods Find Exp Clin Pharmacol. 2001;23:501–503. [PubMed] [Google Scholar]
102. Gonlachanvit S, Chen YH, Hasler WL, Sun WM, Owyang C. Ginger reduces hyperglycemia-evoked gastric dysrhythmias in healthy humans: possible role of endogenous prostaglandins. J Pharmacol Exp Ther. 2003;307:1098–1103. [PubMed] [Google Scholar]
103. Wang L. Clinical observation on acupuncture treatment in 35 cases of diabetic gastroparesis. J Tradit Chin Med. 2004;24:163–165. [PubMed] [Google Scholar]
104. Tack J, Piessevaux H, Coulie B, Caenepeel P, Janssens J. Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology. 1998;115:1346–1352. [PubMed] [Google Scholar]
105. Tack J, Broekaert D, Coulie B, Fischler B, Janssens J. Influence of the selective serotonin re-uptake inhibitor, paroxetine, on gastric sensorimotor function in humans. Aliment Pharmacol Ther. 2003;17:603–608. [PubMed] [Google Scholar]
106. Coulie B, Tack J, Sifrim D, Andrioli A, Janssens J. Role of nitric oxide in fasting gastric fundus tone and in 5-HT1 receptor-mediated relaxation of gastric fundus. Am J Physiol. 1999;276:G373–G377. [PubMed] [Google Scholar]
107. Hasler WL. Gastroparesis: symptoms, evaluation, and treatment. Gastroenterol Clin North Am. 2007;36:619–647, ix. [PubMed] [Google Scholar]
108. Hasler WL, Soudah HC, Dulai G, Owyang C. Mediation of hyperglycemia-evoked gastric slow-wave dysrhythmias by endogenous prostaglandins. Gastroenterology. 1995;108:727–736. [PubMed] [Google Scholar]
109. Gorelick AB, Koshy SS, Hooper FG, Bennett TC, Chey WD, Hasler WL. Differential effects of amitriptyline on perception of somatic and visceral stimulation in healthy humans. Am J Physiol. 1998;275:G460–G466. [PubMed] [Google Scholar]
110. Chial HJ, Camilleri M, Ferber I, Delgado-Aros S, Burton D, McKinzie S, Zinsmeister AR. Effects of venlafaxine, buspirone, and placebo on colonic sensorimotor functions in healthy humans. Clin Gastroenterol Hepatol. 2003;1:211–218. [PubMed] [Google Scholar]
111. Gorard DA, Libby GW, Farthing MJ. 5-Hydroxytryptamine and human small intestinal motility: effect of inhibiting 5-hydroxytryptamine reuptake. Gut. 1994;35:496–500. [PMC free article] [PubMed] [Google Scholar]
112. Lacy BE, Crowell MD, Schettler-Duncan A, Mathis C, Pasricha PJ. The treatment of diabetic gastroparesis with botulinum toxin injection of the pylorus. Diabetes Care. 2004;27:2341–2347. [PubMed] [Google Scholar]
113. Arts J, van Gool S, Caenepeel P, Verbeke K, Janssens J, Tack J. Influence of intrapyloric botulinum toxin injection on gastric emptying and meal-related symptoms in gastroparesis patients. Aliment Pharmacol Ther. 2006;24:661–667. [PubMed] [Google Scholar]
114. Gupta P, Rao SS. Attenuation of isolated pyloric pressure waves in gastroparesis in response to botulinum toxin injection: a case report. Gastrointest Endosc. 2002;56:770–772. [PubMed] [Google Scholar]
115. Bromer MQ, Friedenberg F, Miller LS, Fisher RS, Swartz K, Parkman HP. Endoscopic pyloric injection of botulinum toxin A for the treatment of refractory gastroparesis. Gastrointest Endosc. 2005;61:833–839. [PubMed] [Google Scholar]
116. Arts J, Holvoet L, Caenepeel P, Bisschops R, Sifrim D, Verbeke K, Janssens J, Tack J. Clinical trial: a randomized-controlled crossover study of intrapyloric injection of botulinum toxin in gastroparesis. Aliment Pharmacol Ther. 2007;26:1251–1258. [PubMed] [Google Scholar]
117. Friedenberg FK, Palit A, Parkman HP, Hanlon A, Nelson DB. Botulinum toxin A for the treatment of delayed gastric emptying. Am J Gastroenterol. 2008;103:416–423. [PubMed] [Google Scholar]
118. Jones MP, Maganti K. A systematic review of surgical therapy for gastroparesis. Am J Gastroenterol. 2003;98:2122–2129. [PubMed] [Google Scholar]
119. Abell T, McCallum R, Hocking M, Koch K, Abrahamsson H, Leblanc I, Lindberg G, Konturek J, Nowak T, Quigley EM, et al. Gastric electrical stimulation for medically refractory gastroparesis. Gastroenterology. 2003;125:421–428. [PubMed] [Google Scholar]
120. Lin Z, Forster J, Sarosiek I, McCallum RW. Treatment of diabetic gastroparesis by high-frequency gastric electrical stimulation. Diabetes Care. 2004;27:1071–1076. [PubMed] [Google Scholar]
121. McCallum RW, Dusing RW, Sarosiek I, Cocjin J, Forster J, Lin Z. Mechanisms of high-frequency electrical stimulation of the stomach in gastroparetic patients. Conf Proc IEEE Eng Med Biol Soc. 2006;1:5400–5403. [PubMed] [Google Scholar]
122. McCallum R, Lin Z, Wetzel P, Sarosiek I, Forster J. Clinical response to gastric electrical stimulation in patients with postsurgical gastroparesis. Clin Gastroenterol Hepatol. 2005;3:49–54. [PubMed] [Google Scholar]
123. Abell TL, Van Cutsem E, Abrahamsson H, Huizinga JD, Konturek JW, Galmiche JP, VoelIer G, Filez L, Everts B, Waterfall WE, et al. Gastric electrical stimulation in intractable symptomatic gastroparesis. Digestion. 2002;66:204–212. [PubMed] [Google Scholar]
124. Abell T, Lou J, Tabbaa M, Batista O, Malinowski S, Al-Juburi A. Gastric electrical stimulation for gastroparesis improves nutritional parameters at short, intermediate, and long-term follow-up. JPEN J Parenter Enteral Nutr. 2003;27:277–281. [PubMed] [Google Scholar]
125. Lin Z, Sarosiek I, Forster J, McCallum RW. Symptom responses, long-term outcomes and adverse events beyond 3 years of high-frequency gastric electrical stimulation for gastroparesis. Neurogastroenterol Motil. 2006;18:18–27. [PubMed] [Google Scholar]
126. Maranki JL, Lytes V, Meilahn JE, Harbison S, Friedenberg FK, Fisher RS, Parkman HP. Predictive factors for clinical improvement with Enterra gastric electric stimulation treatment for refractory gastroparesis. Dig Dis Sci. 2008;53:2072–2078. [PMC free article] [PubMed] [Google Scholar]
127. Ayinala S, Batista O, Goyal A, Al-Juburi A, Abidi N, Familoni B, Abell T. Temporary gastric electrical stimulation with orally or PEG-placed electrodes in patients with drug refractory gastroparesis. Gastrointest Endosc. 2005;61:455–461. [PubMed] [Google Scholar]
128. Forstner-Barthell AW, Murr MM, Nitecki S, Camilleri M, Prather CM, Kelly KA, Sarr MG. Near-total completion gastrectomy for severe postvagotomy gastric stasis: analysis of early and long-term results in 62 patients. J Gastrointest Surg. 1999;3:15–21, discussion 21-23. [PubMed] [Google Scholar]
129. Murat A, Pouliquen B, Cantarovich D, Lucas B, Bizais Y, Vecchierini MF, Charbonnel B, Galmiche JP, Soulillou JP. Gastric emptying improvement after simultaneous segmental pancreas and kidney transplantation. Transplant Proc. 1992;24:855. [PubMed] [Google Scholar]
130. Hathaway DK, Abell T, Cardoso S, Hartwig MS, el Gebely S, Gaber AO. Improvement in autonomic and gastric function following pancreas-kidney versus kidney-alone transplantation and the correlation with quality of life. Transplantation. 1994;57:816–822. [PubMed] [Google Scholar]
